Morgan Stanley Cuts Tempus AI (NASDAQ:TEM) Price Target to $70.00

Tempus AI (NASDAQ:TEM) had its price target lowered by Morgan Stanley from $85.00 to $70.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities analysts have also issued reports on TEM. Mizuho began coverage on Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 target price for the company. Piper Sandler decreased their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Canaccord Genuity Group lowered their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research report on Wednesday, February 25th. Finally, Robert W. Baird began coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.15.

Tempus AI Stock Up 3.4%

Shares of Tempus AI stock opened at $53.05 on Tuesday. The business has a fifty day simple moving average of $60.35 and a 200 day simple moving average of $72.78. The stock has a market cap of $9.44 billion, a PE ratio of -37.62 and a beta of 5.29. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52. Tempus AI has a 12 month low of $36.22 and a 12 month high of $104.32.

Insider Transactions at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total value of $1,461,511.20. Following the transaction, the chief financial officer owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. The trade was a 15.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $63.99, for a total transaction of $10,638,337.50. Following the sale, the chief executive officer directly owned 8,974,783 shares of the company’s stock, valued at $574,296,364.17. This represents a 1.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 590,109 shares of company stock valued at $37,056,566. 26.27% of the stock is currently owned by insiders.

Institutional Trading of Tempus AI

A number of institutional investors have recently modified their holdings of the company. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Tempus AI during the fourth quarter worth about $295,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Tempus AI by 38,059.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 27,093 shares of the company’s stock worth $1,600,000 after acquiring an additional 27,022 shares in the last quarter. Virtu Financial LLC raised its holdings in shares of Tempus AI by 384.6% in the fourth quarter. Virtu Financial LLC now owns 54,797 shares of the company’s stock valued at $3,236,000 after purchasing an additional 43,490 shares during the last quarter. Invesco Ltd. lifted its position in shares of Tempus AI by 21.5% in the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock worth $21,947,000 after purchasing an additional 65,836 shares in the last quarter. Finally, Vident Advisory LLC boosted its holdings in Tempus AI by 5.3% during the fourth quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock worth $613,000 after purchasing an additional 522 shares during the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.